Literature DB >> 2839411

The T-cell activating protein (TAP) is up-regulated by endogenous IFN-gamma in activated T cells.

F J Dumont1, R G Palfree, P A Fisher.   

Abstract

The surface expression of the T-cell activating protein (TAP) glycoprotein has been shown to be increased following mitogenic stimulation of T cells. Recently, we found that TAP is also augmented by exogenous interferon-gamma (IFN-gamma) in resting T cells. Because T cells are known to secrete IFN-gamma upon activation, we postulated that TAP enhancement in activated T cells may reflect an autocrine action of endogenous IFN-gamma. This possibility was examined using a potent neutralizing anti-IFN-gamma mAb (H-22.10). Supernatants from Concanavalin A (Con A)-stimulated T cells were found to induce TAP enhancement in resting T cells, and this effect was blocked by the anti-IFN-gamma mAb. Stimulation of T cells with Con A or with the combination of ionomycin plus phorbol myristate acetate produced a marked increase of TAP expression. Addition of the H-22.10 mAb at the initiation of such stimulated T-cell cultures was found to prevent the augmentation of TAP but not to affect the emergence of IL-2 receptors or the increase of Pgp-1 expression. Taken together, these data demonstrate that IFN-gamma is the principal TAP-enhancing mediator released by stimulated T cells. Endogenously produced IFN-gamma, rather than cell activation per se, is thus responsible for the augmentation of TAP expression in stimulated T cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839411      PMCID: PMC1384953     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Biosynthesis, glycosylation, and partial N-terminal amino acid sequence of the T-cell-activating protein TAP.

Authors:  H Reiser; J Coligan; B Benacerraf; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

2.  Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity.

Authors:  R D Schreiber; L J Hicks; A Celada; N A Buchmeier; P W Gray
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

3.  Mitogens as probes for immunocyte activation and cellular cooperation.

Authors:  J Andersson; O Sjöberg; G Möller
Journal:  Transplant Rev       Date:  1972

4.  Stimulation of T cells via the TAP molecule, a member in a family of activating proteins encoded in the Ly-6 locus.

Authors:  E T Yeh; H Reiser; J Daley; K L Rock
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

5.  Mouse lymphocytes with and without surface immunoglobulin: preparative scale separation in polystyrene tissue culture dishes coated with specifically purified anti-immunoglobulin.

Authors:  M G Mage; L L McHugh; T L Rothstein
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

6.  Expression of Pgp-1 (or Ly24) by subpopulations of mouse thymocytes and activated peripheral T lymphocytes.

Authors:  F Lynch; G Chaudhri; J E Allan; P C Doherty; R Ceredig
Journal:  Eur J Immunol       Date:  1987-01       Impact factor: 5.532

7.  Lack of inhibition of mitogen-induced lymphoproliferation by interferon gamma.

Authors:  F Pischedda; S Landolfo; H Kirchner
Journal:  Eur J Immunol       Date:  1985-04       Impact factor: 5.532

8.  Alterations of the T-cell population in BXSB mice: early imbalance of 9F3-defined Lyt-2+ subsets occurs in the males with rapid onset lupic syndrome.

Authors:  F J Dumont; R C Habbersett
Journal:  Cell Immunol       Date:  1986-08       Impact factor: 4.868

9.  Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester.

Authors:  A Truneh; F Albert; P Golstein; A M Schmitt-Verhulst
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

10.  TAP, a novel T cell-activating protein involved in the stimulation of MHC-restricted T lymphocytes.

Authors:  K L Rock; E T Yeh; C F Gramm; S I Haber; H Reiser; B Benacerraf
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.